« Back
Home /
PRGL493

PRGL493

Item no.	HY-139180-5mg
Manufacturer	MedChem Express
CASRN	2479378-45-3
Amount	5 mg
Quantity options	100 mg 10 mg 25 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Molecules
Specific against	other
Purity	99.64
Formula	C25H21N7O2
Citations	[1]Ana F Castillo, et al. New inhibitor targeting Acyl-CoA synthetase 4 reduces breast and prostate tumor growth, therapeutic resistance and steroidogenesis. Cell Mol Life Sci. 2021 Mar;78(6):2893-2910. [2]Wang Y, et al. ACSL4 and polyunsaturated lipids support metastatic extravasation and colonization. Cell. 2024 Nov 19:S0092-8674(24)01270-4
Smiles	O=C(C)NC1=NC(C2=CN(C3=CC=CC=C3)N=C2C4=CC=C(C)O4)N5C6=C(C=CC=C6)NC5=N1
ECLASS 10.1	32169090
ECLASS 11.0	32169090
UNSPSC	12000000
Shipping condition	Cool pack
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	Ferroptosis
Shipping Temperature	Blue Ice
Molecular Weight	451.48
Product Description	PRGL493 is a potent and selective long-chain acyl-CoA synthetase 4 (ACSL4) inhibitor. PRGL493 blocks cell proliferation and tumor growth in both breast and prostate cellular and animal models. PRGL493 can be used for ferroptosis and tumor metastasis research[1][2].
Manufacturer - Research Area	Cancer
Solubility	DMSO : 5 mg/mL (ultrasonic; warming; heat to 60°C)
Manufacturer - Pathway	Apoptosis
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 5 mg

available

Request delivery time